Xponance, Inc. Seagen Inc. Transaction History

Xponance, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	BUY	$191.51 - $216.16 $20,683 - $23,345	108 Added 0.55%	19,811 $4.2 Million
Q2 2023 Jul 13, 2023	BUY	$187.64 - $206.25 $210,532 - $231,412	1,122 Added 6.04%	19,703 $3.79 Million
Q1 2023 Apr 17, 2023	BUY	$127.59 - $203.08 $6,762 - $10,763	53 Added 0.29%	18,581 $3.76 Million
Q4 2022 Jan 23, 2023	BUY	$117.37 - $139.17 $284,856 - $337,765	2,427 Added 15.07%	18,528 $0
Q3 2022 Oct 24, 2022	BUY	$135.27 - $180.11 $21,913 - $29,177	162 Added 1.02%	16,101 $2.2 Million

Q2 2022 Aug 02, 2022	BUY	$108.81 - $179.33 $225,671 - $371,930	2,074 Added 14.96%	15,939 $2.82 Million
Q1 2022 Apr 20, 2022	BUY	$119.61 - $157.85 $18,300 - $24,151	153 Added 1.12%	13,865 $2 Million
Q4 2021 Jan 31, 2022	BUY	$142.57 - $190.86 $13,829 - $18,513	97 Added 0.71%	13,712 $2.12 Million
Q3 2021 Nov 05, 2021	SELL	$142.45 - $169.82 $84,900 - $101,212	-596 Reduced 4.19%	13,615 $2.31 Million
Q2 2021 Aug 12, 2021	BUY	$135.08 - $161.1 $133,323 - $159,005	987 Added 7.46%	14,211 $2.24 Million
Q1 2021 May 10, 2021	BUY	$137.51 - $190.8 $6,600 - $9,158	48 Added 0.36%	13,224 $1.84 Million
Q4 2020 Feb 11, 2021	BUY	$164.63 - $211.93 $2.17 Million - $2.79 Million	13,176 New	13,176 $2.31 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Xponance, Inc., based on Form 13F filings with the SEC.

Stay updated on Xponance, Inc. with notifications on news.